Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

2(40%)

Results Posted

100%(2 trials)

Terminated

1(20%)

Phase Distribution

Ph not_applicable

40%

Ph phase_4

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 4Post-market surveillance

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Terminated(1)

Detailed Status

Completed2

Active, not recruiting1

Recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 41 (33.3%)

N/A2 (66.7%)

Trials by Status

active_not_recruiting120%

completed240%

recruiting120%

terminated120%

Recent Activity

2 active trials

Showing 5 of 5

active_not_recruitingphase_4

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

NCT02162849

recruiting

Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification

NCT06674772

completednot_applicable

Clinical Trials (5)

Showing 5 of 5 trials

NCT02162849Phase 4

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

Active Not Recruiting

NCT06674772

Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification

Recruiting

NCT02157610Not Applicable

Smoking Cessation for Cervical Cancer Survivors

Completed

NCT00572858

Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women

Completed

NCT02302859Not Applicable

Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study

Terminated

All 5 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 5